CRP and obesity disorder: Diacylglycerols are associated with a reduction in obesity and adverse cardiovascular events since they decrease the levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), fat accumulation, and platelet aggregation, which are considered CVD risk factors.